# Oxytocin and Cognitive Control in Adult ADHD

> **NCT03136263** · EARLY_PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 24 (actual)

## Conditions studied

- Attention Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Oxytocin nasal spray
- **DRUG:** Placebo nasal spray

## Key facts

- **NCT ID:** NCT03136263
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136263, "Oxytocin and Cognitive Control in Adult ADHD". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03136263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*